The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review,Journal of Pharmaceutical Analysis

当前位置： X-MOL 学术 › J. Pharm. Anal. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review
Journal of Pharmaceutical Analysis ( IF 6.1 ) Pub Date : 2021-03-24 , DOI: 10.1016/j.jpha.2021.03.003
Leonny Dwi Rizkita ₁ , Indwiani Astuti ₁

Affiliation

Since the World Health Organization (WHO) declared COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a pandemic in March 2020, and more than 117 million people worldwide have been confirmed to have been infected. Scientists, medical professionals, and other stakeholders are racing against time to find and develop effective medicines for COVID-19. However, no drug with high efficacy to treat SARS-CoV-2 infection has been approved. With the increasing popularity of gene therapy, scientists have explored the utilization of small RNAs such as microRNAs (miRNAs) as therapeutics. miRNAs are non-coding RNAs with high affinity for the 3′-UTRs of targeted messenger RNAs (mRNAs). Interactions between host cells and viral genomes may induce the upregulation or downregulation of various miRNAs. Therefore, understanding the expression patterns of these miRNAs and their functions will provide insights into potential miRNA-based therapies. This review systematically summarizes the potential targets of miRNA-based therapies for SARS-CoV-2 infection and examines the viability of possible transfection methods.

中文翻译：

基于 miRNA 的疗法治疗严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染的潜力：综述

自世界卫生组织 (WHO) 于 2020 年 3 月宣布由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的新型冠状病毒肺炎 (COVID-19) 为大流行病以来，全球已确认有超过 1.17 亿人感染被感染。科学家、医疗专业人士和其他利益相关者正在与时间赛跑，寻找和开发针对 COVID-19 的有效药物。然而，尚未批准治疗 SARS-CoV-2 感染的高效药物。随着基因治疗的日益普及，科学家们探索了利用小RNA（例如microRNA（miRNA））作为治疗药物。 miRNA 是非编码 RNA，与目标信使 RNA (mRNA) 的 3'-UTR 具有高亲和力。宿主细胞和病毒基因组之间的相互作用可能诱导各种 miRNA 的上调或下调。因此，了解这些 miRNA 的表达模式及其功能将为了解潜在的基于 miRNA 的疗法提供见解。这篇综述系统地总结了基于 miRNA 的 SARS-CoV-2 感染疗法的潜在靶点，并检验了可能的转染方法的可行性。

更新日期：2021-03-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文